

PHARMANUTRA S.P.A.:

INITIATION OF SHARE BUY-BACK PROGRAM

Pisa, 3 October 2025 – [PharmaNutra S.p.A.](#) (MTA; Ticker PHN), a group of companies specialized in mineral supplements and medical devices for muscles and joints, announces the beginning of a share buyback program, previously authorized by the Shareholders' Meeting of April 16th, 2025.

In light of the current economic landscape, the founders and management reaffirm their confidence in the company, the uniqueness and innovation of its products, and the new expansion initiatives, continuing to invest in resources to ensure sustainable and meaningful growth.

There are no reasons for concern that can justify the current performance of the stock. The financial management is strong, growth continues, and the company is working to maximize value for all investors.

The announcement of the initiation of the share buyback program is a clear signal of confidence in the company's financial health and represents an opportunity for value creation for shareholders, once again demonstrating the long-term commitment to their success.

The program is aimed at allowing the Company to seize the opportunity to make an advantageous investment, in cases where the market price of PHN shares, also due to factors external to the Company, is not able to adequately express the value of the same, and therefore to provide the Company with a useful strategic investment opportunity for all purposes permitted by current regulations.

The purchase of shares within the scope of the program is done with the modalities and within the operating limits laid down in the decision referred to above, by Article 5 of (EU) Regulation no. 596/2014 (Market Abuse Regulation), by Article 3 of the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 and by the general and industry legislation in force, in particular:

- purchases will be for a maximum overall of 24,500 ordinary shares of the Company without indication of nominal value to a maximum value of EUR 1,100,000;
- such purchases will be made with a consideration that is not higher than the highest price of the last independent operation and the highest current independent bid on the trading venues where the purchase is carried out, it being understood that the price cannot be lower than a minimum of

Pharmanutra S.p.A.

Via Campodavola, 1 - 56122 Pisa | +39 050 7846500

[pharmanutragroup.com](#) | [pharmanutra.it](#) | [info@pharmanutra.it](#) | [pharmanutra@pec.it](#)

C.F. / P.Iva / Reg. Impr. 01679440501 - Codice SDI SUBM70N | Cap.Soc. € 1.123.097,70 I.V. | REA 146259



20% or higher than a maximum of 10% than the stock price registered at the close of the trading session prior to each single purchase transaction;

- such purchases will be made for quantities not exceeding 25% of the average daily volume of PHN shares in the trading venue where the purchase is carried out, calculated on the basis of the average daily volume traded in the 20 trading days prior to the date of purchase;
- the purchase programme will be realized within 18 months from the date of the Shareholders' Meeting of April 16th, 2025.

Intermonte SIM S.p.A. operates as an intermediary responsible for purchases within the scope of the program. The Company will provide information with regard to the transactions relating to the program for the purchase of own shares, in accordance with the terms and conditions required by the applicable regulation. Any subsequent change to the above-described buy-back plan will be promptly disclosed by the Company.

As at the date of this press release, PharmaNutra holds n. 90,155 treasury shares in portfolio equal to 0.93% of the share capital.

PharmaNutra S.p.A.

Founded and led by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra is a company established in 2003 that develops unique nutritional supplements and innovative medical devices, taking care of the entire production process, from proprietary raw materials to the finished product. PharmaNutra is a leader in the production of iron-based nutritional supplements under the SiderAL® brand, where it holds important patents on Sucrosomal® Technology, and is considered one of the emerging top players in the medical device sector dedicated to restoring joint capacity thanks to the Cetilar® brand. The effectiveness of the products is demonstrated by a number of scientific evidence, including more than 120 publications. In Italy, the sales activity is carried out through a network of over 160 Commercial Scientific Informants serving the medical class and dedicated to the exclusive marketing of products to pharmacies and parapharmacies throughout the national territory. Sales abroad are guaranteed in over 71 countries through 45 partners selected among the leading pharmaceutical companies. Over the years, the Group has developed a precise strategy in the management and production of intellectual property, based on the integrated management of all components: proprietary raw materials, patents, trademarks and clinical evidence.

PharmaNutra.it

For further information:

PharmaNutra S.p.A.

Press Office - Spriano Communication & Partners

PharmaNutra S.p.A.

Via Campodavola, 1 - 56122 Pisa | +39 050 7846500
pharmanutragroup.com | pharmanutra.it | info@pharmanutra.it | pharmanutra@pec.it
C.F. / P.Iva / Reg. Impr. 01679440501 - Codice SDI SUBM70N | Cap.Soc. € 1.123.097,70 I.V. | REA 146259



Via Campo da Vela, 1 - 56122 Pisa

Tel. +39 050 7846500

investorrelation@PharmaNutra.it

Internal Press Office

press@calabughi.com

Via Santa Radegonda, 16 - 20121 Milan

Tel. +39 02 83635708

Matteo Russo

mrusso@sprianocommunication.com

Cristina Tronconi

ctronconi@sprianocommunication.com

Pharmanutra S.p.A.

Via Campodavella, 1 - 56122 Pisa | +39 050 7846500

pharmanutragroup.com | pharmanutra.it | info@pharmanutra.it | pharmanutra@pec.it

C.F. / P.Iva / Reg. Impr. 01679440501 - Codice SDI SUBM70N | Cap.Soc. € 1.123.097,70 I.V. | REA 146259

